{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:06:37Z","timestamp":1787951197047,"version":"build-2784847793"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Mycoses fungoides (MF) and S\u00e9zary syndrome (SS) are cutaneous T-cell lymphomas that are often challenging to manage given the absence of reliably curative therapies, at times high symptom burden with significant detriment to quality of life, and need for ongoing treatment for disease and symptom control. Recent developments in skin-directed treatments include optimizing the use of existing topical therapies, the introduction of known dermatological agents and treatment modalities for the specific treatment of MF\/SS (such as mechlorethamine gel, calcineurin inhibitor creams, and photodynamic therapy), and novel local and topical agents. For advanced disease, dedicated clinical trials have translated to exciting progress, leading to the approval of brentuximab vedotin (2017) and mogamulizumab (2018) for relapsed MF\/SS. Additional studies of other active systemic agents, including various cellular therapies, represent further attempts to add to the therapeutic armamentarium in treating MF\/SS. In this review, we highlight these recent advancements, ranging from optimization of skin-directed therapies to the introduction of novel systemic agents. We focus on therapies approved in the preceding five years or under investigation in advanced-phase clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1284045","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:19:20Z","timestamp":1696511960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Advances in the treatment of mycoses fungoides and S\u00e9zary syndrome: a narrative update in skin-directed therapies and immune-based treatments"],"prefix":"10.3389","volume":"14","author":[{"given":"Robert","family":"Stuver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamir","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405044","article-title":"S\u00e9zary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3","volume":"22","author":"Booken","year":"2008","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153031","article-title":"Oncogenomic analysis of mycosis fungoides reveals major differences with S\u00e9zary syndrome","volume":"113","author":"van Doorn","year":"2009","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-251926","article-title":"S\u00e9zary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous LymphomInternational Consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: Validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2003.01639.x","article-title":"Treatment of patch-stage mycosis fungoides with topical corticosteroids","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: A consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.01.047","article-title":"Low-dose (10-Gy) total skin electron beam therapy for cutaneous t-cell lymphoma: An open clinical study and pooled data analysis","volume":"92","author":"Kamstrup","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"B16","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.3.208","article-title":"Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kaplan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or S\u00e9zary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: A subgroup efficacy analysis from the PROPEL study","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B28","first-page":"581","article-title":"How we treat mycosis fungoides and s\u00e9zary syndrome","volume":"19","author":"Khan","year":"2021","journal-title":"Clin Adv Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19237","article-title":"Mechanism of action of chlormethine gel in mycosis fungoides","volume":"37","author":"Guenova","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00591-x","article-title":"The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"22","author":"Kim","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00831-w","article-title":"Maintenance and concomitant therapy use with chlormethine gel among patients with stage IA\/IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): A real-world evidence study","volume":"12","author":"Querfeld","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.02.002","article-title":"Response to chlormethine\/mechlorethamine gel maintenance treatment regimen in patients with mycosis fungoides: A single-center retrospective study","volume":"22","author":"Correia","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.896","article-title":"Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: A phase 2 extension study","volume":"87","author":"Querfeld","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00107-7","article-title":"Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial","volume":"9","author":"Ortiz-Romero","year":"2022","journal-title":"Lancet Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15162","article-title":"Usage and safety of topical tacrolimus in patients with mycosis fungoides","volume":"47","author":"Weiner","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00787-3","article-title":"Association between the use of topical calcineurin inhibitors and the risk of cancer among patients with atopic dermatitis: A nationwide, population-based, retrospective cohort study","volume":"24","author":"Huang","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/CLEP.S331287","article-title":"Long-term risk of skin cancer and lymphoma in users of topical tacrolimus and pimecrolimus: final results from the extension of the cohort study protopic joint European longitudinal lymphoma and skin cancer evaluation (JOELLE)","volume":"13","author":"Arana","year":"2021","journal-title":"Clin Epidemiol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15840","article-title":"Short-term efficacy and safety of total skin electron beam therapy in mycosis fungoides: Systematic review and meta-analysis","volume":"35","author":"Grandi","year":"2022","journal-title":"Dermatol Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2023.03.015","article-title":"Single-fraction radiation therapy for localized cutaneous T-cell lymphoma","volume":"13","author":"Wang","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141119","article-title":"Photodynamic therapy in refractory mycosis fungoides: A prospective, open-label study","volume":"136","author":"Brumfiel","year":"2020","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/pharmaceutics15051328","article-title":"An update on recent advances of photodynamic therapy for primary cutaneous lymphomas","volume":"15","author":"Liu","year":"2023","journal-title":"Pharmaceutics"},{"key":"B42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/pharmaceutics15010047","article-title":"Photodynamic therapy as an effective treatment for cutaneous lymphomas","volume":"15","author":"Caccavale","year":"2022","journal-title":"Pharmaceutics"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00278.x","article-title":"Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and Malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders","volume":"111","author":"Fox","year":"1998","journal-title":"J Invest Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.2749","article-title":"Efficacy and safety of topical hypericin photodynamic therapy for early-stage cutaneous T-cell lymphoma (Mycosis fungoides): the FLASH phase 3 randomized clinical trial","volume":"158","author":"Kim","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16050","article-title":"The efficacy of 308-nm excimer laser in the treatment of mycosis fungoides","volume":"62","author":"Sosh","year":"2023","journal-title":"Int J Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.3390\/cells11223591","article-title":"Targeting the CD47-SIRP\u03b1 Axis: present therapies and the future for cutaneous T-cell lymphoma","volume":"11","author":"Xiao","year":"2022","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00271-4","article-title":"Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or S\u00e9zary syndrome: a multicentre, phase 1 study","volume":"8","author":"Querfeld","year":"2021","journal-title":"Lancet Haematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125118","article-title":"A phase 1b study evaluating the safety and efficacy of topical administration of WP1220, an inhibitor of STAT3 activation, in stage I, II or III mycosis fungoides (MF)","volume":"134","author":"Soko\u0142owska-Wojdy\u0142o","year":"2019","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890470111018","article-title":"Improved discriminative and evaluative capability of a refined version of skindex, a quality-of-life instrument for patients with skin diseases","volume":"133","author":"Chren","year":"1997","journal-title":"Arch Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: A multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20588","article-title":"Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and S\u00e9zary syndrome with variable CD30 positivity","volume":"185","author":"Papadavid","year":"2021","journal-title":"Br J Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac137","article-title":"Response to brentuximab vedotin by CD30 expression in non-hodgkin lymphoma","volume":"27","author":"Jagadeesh","year":"2022","journal-title":"Oncologist"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162375","article-title":"Real-world treatment patterns and clinical outcomes with brentuximab vedotin or other standard therapies in patients with previously treated cutaneous T-cell lymphoma (CTCL): A retrospective chart review study in the United States","volume":"140","author":"Barta","year":"2022","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/hon.123_2880","article-title":"A phase II trial of reduced dose brentuximab vedotin for cutaneous T-cell lymphomas","volume":"39","author":"Khan","year":"2021","journal-title":"Hematol Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141379","article-title":"Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001587","article-title":"Histopathologic characterization of mogamulizumab-associated rash","volume":"44","author":"Wang","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or s\u00e9zary syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013341","article-title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients","volume":"139","author":"de Masson","year":"2022","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166887","article-title":"Mogamulizumab-associated rash (MAR) correlates with longer progression free survival in cutaneous T cell lymphoma (CTCL)","volume":"140","author":"Hu","year":"2022","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(20)30849-1","article-title":"TCL-127: impact of concomitant steroids on mogamulizumab efficacy in MAVORIC","volume":"20","author":"Akilov","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014468","article-title":"Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma","volume":"139","author":"Beygi","year":"2022","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by hu5F9-G4 and rituximab in non-hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150543","article-title":"A pilot phase I trial of IL-21 expanded ideal-donor natural killer (NK) cells in combination with mogamulizumab in patients with cutaneous T-cell lymphomas (CTCL) or adult T-cell leukemia\/lymphomas (ATLL)","volume":"138","author":"William","year":"2021","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.05.017","article-title":"Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease","volume":"22","author":"Sugio","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.315","article-title":"Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality","volume":"51","author":"Inoue","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.254","article-title":"Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia\/lymphoma","volume":"51","author":"Haji","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004045","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"137","author":"Cook","year":"2021","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167564","article-title":"Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302","volume":"140","author":"Prince","year":"2022","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166916","article-title":"Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302","volume":"140","author":"Foss","year":"2022","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3185","article-title":"Usefulness of KIR3DL2 to diagnose, follow-up, and manage the treatment of patients with s\u00e9zary syndrome","volume":"23","author":"Hurabielle","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160239","article-title":"Lacutamab in patients with advanced sezary syndrome: results from an interim analysis of the tellomak phase 2 trial","volume":"140","author":"Bagot","year":"2022","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_127","article-title":"LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF): EFFICACY RESULTS ACCORDING TO UPDATED LYMPH NODE (LN) CLASSIFICATION IN THE TELLOMAK STUDY","volume":"41","author":"Kim","year":"2023","journal-title":"Hematol Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001966","article-title":"Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas","volume":"4","author":"Neuwelt","year":"2020","journal-title":"Blood Adv"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-216671","article-title":"B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181cc7e79","article-title":"PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis","volume":"34","author":"Krishnan","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia\u2013lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"New Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and s\u00e9zary syndrome: A multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002371","article-title":"Pembrolizumab in mycosis fungoides with PD-L1 structural variants","volume":"5","author":"Beygi","year":"2021","journal-title":"Blood Adv"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170181","article-title":"Pembrolizumab in combination with epigenetic therapy is safe and active in heavily treated patients with peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL): preliminary results from the embolden trial","volume":"140","author":"Roberts","year":"2022","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143354","article-title":"Phase 1 results of anti-PD-ligand 1 (Durvalumab) & Lenalidomide in patients with cutaneous T cell lymphoma and correlation with programmed death ligand 1 expression and gene expression profile","volume":"136","author":"Querfeld","year":"2020","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2536","article-title":"Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis","volume":"107","author":"Sors","year":"2006","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1182\/blood.2022018669","article-title":"Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study","volume":"142","author":"Nicolay","year":"2023","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: THE COBALT-LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70-TARGETED ALLOGENEIC CRISPR-CAS9\u2013ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED\/REFRACTORY (R\/R) T-CELL MALIGNANCIES","volume":"6","author":"Iyer","year":"2022","journal-title":"Hemasphere"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3148","article-title":"A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale","volume":"38","author":"Choe-Juliak","year":"2020","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell Malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148102","article-title":"CD30-directed CAR-T cells co-expressing CCR4 in relapsed\/refractory hodgkin lymphoma and CD30+ Cutaneous T cell lymphoma","volume":"138","author":"Grover","year":"2021","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-158681","article-title":"Tub-010, a novel antibody-drug-conjugate with reduced nonspecific toxicity profile based on tub-tag technology widens the therapeutic window for the treatment of CD30+ Malignancies","volume":"140","author":"Gerlach","year":"2022","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26288","article-title":"Romidepsin and lenalidomide-based regimens have efficacy in relapsed\/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts","volume":"96","author":"Mehta-Shah","year":"2021","journal-title":"Am J Hematol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/hon.56_2879","article-title":"The combination of duvelisib and romidepsin (DR) is highly active against relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: final results and biomarker analysis","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1284045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T13:19:26Z","timestamp":1696511966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1284045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":99,"alternative-id":["10.3389\/fimmu.2023.1284045"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1284045","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"article-number":"1284045"}}